How To Avert Biopharma's R&D Crisis
Executive SummaryUsing target-based drug discovery to produce blockbusters on demand has led the biopharma industry down the wrong path. It’s time to get back to basics and focus on breakthrough science. The author suggests a formula for success.
You may also be interested in...
The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.
Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug; FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.